Investigational New Drugs

, Volume 29, Issue 1, pp 167–174 | Cite as

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

  • Rafal Wierzbicki
  • Derek J. Jonker
  • Malcolm J. Moore
  • Scott R. Berry
  • Patrick J. Loehrer
  • Hagop Youssoufian
  • Eric K. Rowinsky
PHASE II STUDIES

Summary

Purpose To determine antitumor activity of cetuximab monotherapy in patients with refractory metastatic colorectal carcinoma (mCRC) with lack of specific membrane immunostaining for the epidermal growth factor receptor (EGFR). Patients and methods Patients had immunohistochemical (IHC)-determined mCRC with absent EGFR immunostaining that progressed after receiving at least one standard, fluoropyrimidine-containing chemotherapeutic regimen. Absent EGFR immunostaining was defined as the IHC absence of specific membrane staining in ≥500 cancer cells examined in well-preserved tissue. The study was performed prior to results of studies linking cetuximab sensitivity to K-ras mutation status. Patients received 400 mg/m2 of intravenous (i.v.) cetuximab followed by once-weekly i.v. cetuximab 250 mg/m2 until disease progression or unacceptable toxicity. Patients were evaluated for objective response at least every 6 weeks. Kaplan-Meier estimates were calculated for duration of response, time to progression (TTP), and overall survival (OS). Results Seven (8.2%) of 85 mCRC patients whose tumors lacked EGFR immunostaining had major responses following cetuximab treatment. The median duration of response was 5.1 months. Median TTP and OS were 2.5 months and 10.0 months, respectively; the 1-year survival rate was 39.6%. The most frequently reported cetuximab-related adverse events were acneiform dermatitis, fatigue, headache, and dry skin. Conclusion Cetuximab monotherapy produces objective antitumor activity in patients with mCRC that does not express EGFR as determined by IHC. The activity and safety profiles of cetuximab monotherapy in mCRC lacking EGFR immunostaining are similar to previous observations in EGFR IHC-positive disease that was not selected based on K-ras mutation status.

Keywords

Immunohistochemistry (IHC) Cetuximab Epidermal growth factor receptor (EGFR) Immunostaining Metastatic colorectal cancer (mCRC) 

References

  1. 1.
    Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232CrossRefPubMedGoogle Scholar
  2. 2.
    McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38:2258–2264CrossRefPubMedGoogle Scholar
  3. 3.
    Mendelsohn J, Kawamoto T, Sato G, Sato J. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. United States Patent #4,943,533. July 24, 1990Google Scholar
  4. 4.
    Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318PubMedGoogle Scholar
  5. 5.
    Waksal HW (1999) Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 18:427–436CrossRefPubMedGoogle Scholar
  6. 6.
    Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157CrossRefPubMedGoogle Scholar
  7. 7.
    Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 24:4914–4921CrossRefPubMedGoogle Scholar
  8. 8.
    Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMedGoogle Scholar
  9. 9.
    Jonker DJ, O’Callaghan CJ, Karapetis CS (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMedGoogle Scholar
  10. 10.
    Erbitux [package insert] (2008) ImClone Systems, BranchburgGoogle Scholar
  11. 11.
    Spaulding DC, Spaulding BO (2002) Epidermal growth factor receptor expression and measurement in solid tumors. Seminars Oncol 29:45–54Google Scholar
  12. 12.
    Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22:4772–4778CrossRefPubMedGoogle Scholar
  13. 13.
    Atkins D, Reiffen K-A, Tegtmeier C, Winther H, Bonato MS, Störkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52:893–901CrossRefPubMedGoogle Scholar
  14. 14.
    Dei Tos AP, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods. Eur J Cancer 41:1383–1392CrossRefPubMedGoogle Scholar
  15. 15.
    Hebbar M, Wacrenier AS, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:855–857CrossRefPubMedGoogle Scholar
  16. 16.
    Saltz L, Meropol N, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208CrossRefPubMedGoogle Scholar
  17. 17.
    Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810CrossRefPubMedGoogle Scholar
  18. 18.
    Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMedGoogle Scholar
  19. 19.
    Van Cutsem E, Köhne C-H, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMedGoogle Scholar
  20. 20.
    Bokemeyer C, Bondarenko I, Makhson A et al (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671CrossRefPubMedGoogle Scholar
  21. 21.
    World Health Organization (1979) WHO handbook of reporting results of cancer treatment. WHO Publications Centre USA, Albany, pp 1–45Google Scholar
  22. 22.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  23. 23.
    Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346CrossRefPubMedGoogle Scholar
  24. 24.
    Adams EJ, Green JA, Clark AH, Youngson JH (1999) Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 52:75–77CrossRefPubMedGoogle Scholar
  25. 25.
    Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Luukkaala T, Tammela TL, Martikainen PM (2003) Membranous location of EGFR is associated with good prognosis in renal cell carcinoma. Br J Cancer 89:1266–1269CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Rafal Wierzbicki
    • 1
  • Derek J. Jonker
    • 2
  • Malcolm J. Moore
    • 3
  • Scott R. Berry
    • 4
  • Patrick J. Loehrer
    • 5
  • Hagop Youssoufian
    • 6
  • Eric K. Rowinsky
    • 6
  1. 1.Consultant Medical Oncologist Durham Regional Cancer CentreOshawaCanada
  2. 2.Gastrointestinal Disease Site Group, Cancer Care Ontario, Program in Evidence-Based CareThe Ottawa Hospital Regional Cancer CentreOttawaCanada
  3. 3.Princess Margaret HospitalTorontoCanada
  4. 4.Sunnybrook Odette Cancer CentreTorontoCanada
  5. 5.Indiana University School of Medicine Cancer CenterIndianapolisUSA
  6. 6.ImClone Systemsa Wholly-Owned Subsidiary of Eli Lilly & CoBranchburgUSA

Personalised recommendations